Visnagin: A novel cardioprotective agent against anthracycline toxicity (Review)

Obeidat,Omar; Obeidat,Ali; Obeidat,Abedallah; Ismail,Mohamed F.

doi:10.3892/mi.2024.161

Visnagin: A novel cardioprotective agent against anthracycline toxicity (Review)

Authors:
- Omar Obeidat
- Ali Obeidat
- Abedallah Obeidat
- Mohamed F. Ismail
View Affiliations

Affiliations: Graduate Medical Education Program, College of Medicine, University of Central Florida, Orlando, FL 32816, USA, Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan
Published online on: May 13, 2024 https://doi.org/10.3892/mi.2024.161
Article Number: 37
Copyright : © Obeidat et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Doxorubicin (DOX), a cornerstone of cancer chemotherapy, is marred by its dose‑dependent cardiotoxicity, leading to cardiomyopathy and heart failure. The epidemiology of DOX‑related cardiotoxicity highlights its cumulative, progressive nature, with a significant impact on the health of patients. The pathophysiological mechanisms involve mitochondrial dysfunction, oxidative stress and disrupted calcium homeostasis in cardiomyocytes. Despite the search for effective cardioprotective strategies, current treatments offer limited efficacy. Visnagin emerges as a potential solution, known for its vasodilatory and anti‑inflammatory properties, and recent studies suggest its cardioprotective efficacy against DOX‑induced cardiotoxicity through mitochondrial protection, the modulation of key signaling pathways and the inhibition of apoptosis. The present review aimed to provide a comprehensive overview of the mechanisms of action of visnagin, as well as to provide experimental evidence, and potential integration into cancer treatment regimens, highlighting its promise as a novel therapeutic agent for managing cardiotoxicity in patients undergoing anthracycline chemotherapy.

View Figures

View References

1	Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS and Moreira PI: Doxorubicin: The good the bad and the ugly effect. Curr Med Chem. 16:3267–3285. 2009.PubMed/NCBI View Article : Google Scholar
2	Bristow MR, Mason JW, Billingham ME and Daniels JR: Doxorubicin cardiomyopathy: Evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med. 88:168–175. 1978.PubMed/NCBI View Article : Google Scholar
3	Singal PK and Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med. 339:900–905. 1998.PubMed/NCBI View Article : Google Scholar
4	Swain SM, Whaley FS and Ewer MS: Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer. 97:2869–2879. 2003.PubMed/NCBI View Article : Google Scholar
5	Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D and Cipolla CM: Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 66:309–325. 2016.PubMed/NCBI View Article : Google Scholar
6	Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N and Sawyer DB: Anthracycline cardiotoxicity: From bench to bedside. J Clin Oncol. 26:3777–3784. 2008.PubMed/NCBI View Article : Google Scholar
7	Salvatorelli E, Menna P, Chello M, Covino E and Minotti G: Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from lowdose doxorubicin. J Pharmacol Exp Ther. 362:263–270. 2017.PubMed/NCBI View Article : Google Scholar
8	Minotti G, Menna P, Salvatorelli E, Cairo G and Gianni L: Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 56:185–229. 2004.PubMed/NCBI View Article : Google Scholar
9	Wallace KB: Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc Toxicol. 7:101–107. 2007.PubMed/NCBI View Article : Google Scholar
10	Lebrecht D, Kokkori A, Ketelsen UP, Setzer B and Walker UA: Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J Pathol. 207:436–444. 2005.PubMed/NCBI View Article : Google Scholar
11	Simůnek T, Stérba M, Popelová O, Adamcová M, Hrdina R and Gersl V: Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep. 61:154–171. 2009.PubMed/NCBI View Article : Google Scholar
12	Herman EH, Mhatre RM, Lee IP and Waravdekar VS: Prevention of the cardiotoxic effects of adriamycin and daunomycin in the isolated dog heart. Proc Soc Exp Biol Med. 140:234–239. 1972.PubMed/NCBI View Article : Google Scholar
13	Hasinoff BB, Hellmann K, Herman EH and Ferrans VJ: Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem. 5:1–28. 1998.PubMed/NCBI
14	Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, Mendenhall NP, Sposto R, Chauvenet A and Schwartz CL: Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol. 25:493–500. 2007.PubMed/NCBI View Article : Google Scholar
15	Batanouny KH: Wild medicinal plants in Egypt: An inventory to support conservation and sustainable use. Acad of Scientific Research & Technology, 2001.
16	Lee JK, Jung JS, Park SH, Park SH, Sim YB, Kim SM, Ha TS and Suh HW: Anti-inflammatory effect of visnagin in lipopolysaccharide-stimulated BV-2 microglial cells. Arch Pharm Res. 33:1843–1850. 2010.PubMed/NCBI View Article : Google Scholar
17	Bhagavathula AS, Al-Khatib AJ, Elnour AA, Al Kalbani NM and Shehab A: Ammi Visnaga in treatment of urolithiasis and hypertriglyceridemia. Pharmacognosy Res. 7:397–400. 2014.PubMed/NCBI View Article : Google Scholar
18	Khalil N, Bishr M, Desouky S and Salama O: Ammi Visnaga L., a potential medicinal plant: A review. Molecules. 25(301)2020.PubMed/NCBI View Article : Google Scholar
19	Pasari LP, Khurana A, Anchi P, Saifi MA, Annaldas S and Godugu C: Visnagin attenuates acute pancreatitis via Nrf2/NFκB pathway and abrogates associated multiple organ dysfunction. Biomed Pharmacother. 112(108629)2019.PubMed/NCBI View Article : Google Scholar
20	Vuong JT, Stein-Merlob AF, Cheng RK and Yang EH: Novel therapeutics for Anthracycline induced cardiotoxicity. Front Cardiovasc Med. 9(863314)2022.PubMed/NCBI View Article : Google Scholar
21	Cantrell CL, Travaini ML, Bajsa-Hirschel J, Svendsen LD, Reichley A, Sosa GM, Kim SJ, Tamang P, Meepagala K and Duke SO: Synthesis, herbicidal activity, and structure-activity relationships of O-Alkyl analogues of Khellin and Visnagin. J Agric Food Chem. 71:14593–14603. 2023.PubMed/NCBI View Article : Google Scholar
22	Duarte J, Torres AI and Zarzuelo A: Cardiovascular effects of visnagin on rats. Planta Med. 66:35–39. 2000.PubMed/NCBI View Article : Google Scholar
23	Xi L: Visnagin-a new protectant against doxorubicin cardiotoxicity? Inhibition of mitochondrial malate dehydrogenase 2 (MDH2) and beyond. Ann Transl Med. 4(65)2016.PubMed/NCBI View Article : Google Scholar
24	Huang CC, Monte A, Cook JM, Kabir MS and Peterson KP: Zebrafish heart failure models for the evaluation of chemical probes and drugs. Assay Drug Dev Technol. 11:561–572. 2013.PubMed/NCBI View Article : Google Scholar
25	Liu Y, Asnani A, Zou L, Bentley VL, Yu M, Wang Y, Dellaire G, Sarkar KS, Dai M, Chen HH, et al: Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase. Sci Transl Med. 6(266ra170)2014.PubMed/NCBI View Article : Google Scholar
26	Asnani A, Zheng B, Liu Y, Wang Y, Chen HH, Vohra A, Chi A, Cornella-Taracido I, Wang H, Johns DG, et al: Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity. JCI Insight. 3(e96753)2018.PubMed/NCBI View Article : Google Scholar
27	Nielsen TT, Støttrup NB, Løfgren B and Bøtker HE: Metabolic fingerprint of ischaemic cardioprotection: Importance of the malate-aspartate shuttle. Cardiovasc Res. 91:382–391. 2011.PubMed/NCBI View Article : Google Scholar
28	Lam PY, Kutchukian P, Anand R, Imbriglio J, Andrews C, Padilla H, Vohra A, Lane S, Parker DL Jr, Taracido IC, et al: Cyp1 inhibition prevents Doxorubicin-Induced Cardiomyopathy in a Zebrafish heart-failure model. Chembiochem. 21:1905–1910. 2020.PubMed/NCBI View Article : Google Scholar
29	Arnold WR and Das A: An emerging pathway of Doxorubicin cardiotoxicity mediated through CYP2J2. Biochemistry. 57:2294–2296. 2018.PubMed/NCBI View Article : Google Scholar
30	Zhang Y, El-Sikhry H, Chaudhary KR, Batchu SN, Shayeganpour A, Jukar TO, Bradbury JA, Graves JP, DeGraff LM, Myers P, et al: Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol. 297:H37–H46. 2009.PubMed/NCBI View Article : Google Scholar
31	Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W and Lipman DJ: Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. Nucleic Acids Res. 25:3389–3402. 1997.PubMed/NCBI View Article : Google Scholar
32	Warburg O: On respiratory impairment in cancer cells. Science. 124:269–270. 1956.PubMed/NCBI
33	Abukhalil MH, Hussein OE, Aladaileh SH, Althunibat OY, Al-Amarat W, Saghir SA, Alfwuaires MA, Algefare AI, Alanazi KM, Al-Swailmi FK, et al: Visnagin prevents isoproterenol-induced myocardial injury by attenuating oxidative stress and inflammation and upregulating Nrf2 signaling in rats. J Biochem Mol Toxicol. 35(e22906)2021.PubMed/NCBI View Article : Google Scholar
34	Fu HR, Li XS, Zhang YH, Feng BB and Pan LH: Visnagin ameliorates myocardial ischemia/reperfusion injury through the promotion of autophagy and the inhibition of apoptosis. Eur J Histochem. 64(3131)2020.PubMed/NCBI View Article : Google Scholar
35	Haug KG, Weber B, Hochhaus G and Butterweck V: Nonlinear pharmacokinetics of visnagin in rats after intravenous bolus administration. Eur J Pharm Sci. 45:79–89. 2012.PubMed/NCBI View Article : Google Scholar
36	Jahan H, Choudhary MI, Shah Z, Khan KM and Rahman AU: Derivatives of 6-nitrobenzimidazole inhibit fructose-mediated protein glycation and intracellular reactive oxygen species production. Med Chem. 13:577–584. 2017.PubMed/NCBI View Article : Google Scholar
37	Aydogmus-Ozturk F, Jahan H, Beyazit N, Gunaydin K and Choudhary MI: The anticancer activity of visnagin, isolated from Ammi visnaga L., against the human malignant melanoma cell lines, HT 144. Mol Biol Rep. 46:1709–1714. 2019.PubMed/NCBI View Article : Google Scholar
38	Vrzal R, Frauenstein K, Proksch P, Abel J, Dvorak Z and Haarmann-Stemmann T: Khellin and visnagin differentially modulate AHR signaling and downstream CYP1A activity in human liver cells. PLoS One. 8(e74917)2013.PubMed/NCBI View Article : Google Scholar